# A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

> **NCT03136653** · PHASE1,PHASE2 · COMPLETED · sponsor: **Molecular Partners AG** · enrollment: 33 (actual)

## Conditions studied

- Multiple Myeloma in Relapse

## Interventions

- **BIOLOGICAL:** MP0250 plus BOR+DEX

## Key facts

- **NCT ID:** NCT03136653
- **Lead sponsor:** Molecular Partners AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-23
- **Primary completion:** 2020-10-12
- **Final completion:** 2021-01-13
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2021-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03136653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03136653, "A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03136653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*